Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Free Cash Flow (2018 - 2025)

Arcturus Therapeutics Holdings' Free Cash Flow history spans 8 years, with the latest figure at -$16.1 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 5582.75% year-over-year to -$16.1 million; the TTM value through Dec 2025 reached -$74.5 million, down 23.36%, while the annual FY2025 figure was -$74.5 million, 23.36% down from the prior year.
  • Free Cash Flow reached -$16.1 million in Q4 2025 per ARCT's latest filing, up from -$17.3 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $163.6 million in Q4 2022 to a low of -$51.2 million in Q1 2022.
  • Average Free Cash Flow over 5 years is -$13.0 million, with a median of -$27.2 million recorded in 2024.
  • Peak YoY movement for Free Cash Flow: skyrocketed 506.35% in 2022, then crashed 5582.75% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$40.3 million in 2021, then surged by 506.35% to $163.6 million in 2022, then tumbled by 101.9% to -$3.1 million in 2023, then surged by 90.88% to -$284000.0 in 2024, then plummeted by 5582.75% to -$16.1 million in 2025.
  • Per Business Quant, the three most recent readings for ARCT's Free Cash Flow are -$16.1 million (Q4 2025), -$17.3 million (Q3 2025), and -$5.8 million (Q2 2025).